Successful use of long-term follow-up in patients with chronic myeloid leukemia with a deep molecular response at reduced doses of 2nd generation tyrosine kinase inhibitors: clinical cases and literature review

• Published in: Terapevtic̆eskii arhiv Vol. 92; no. 7; pp. 90 - 94
• Main Authors: Gurianova, M A, Chelysheva, E Y, Shukhov, O A, Turkina, A G
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) "Consilium Medicum" Publishing house 01.09.2020
• Subjects: adverse effects; chronic myeloid leukemia; Dasatinib; deep molecular response; doses reduction; Family Characteristics; Follow-Up Studies; Humans; imatinib; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; major molecular response; nilotinib; Protein Kinase Inhibitors - adverse effects; tyrosine kinase inhibitors; tyrosine kinase inhibitors; dasatinib; doses reduction; major molecular response; nilotinib; adverse effects; chronic myeloid leukemia; imatinib; deep molecular response
• ISSN: 0040-3660; 2309-5342
• DOI: 10.26442/00403660.2020.07.000789

Therapy with tyrosine kinase inhibitors (TKI) allows to achieve a deep molecular response in 6070% of patients with chronic myeloid leukemia (CML). According to the current guidelines CML patients receive a long-term treatment with TKI in standard dose. The frequently observed adverse effects (AE) of TKI therapy are mostly dose-dependent. A new treatment approach with TKI use in reduced dose is desirable for the CML patients with existing AE or with a high risk of AE occurrence. We report the two cases of successful long-term treatment of CML patients with reduced doses of second generation TKIs. The aim of the TKI dose reduction was to reduce the clinical manifestations of drug toxicities and to prevent the AE.